Ethyl 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161797-99-5 Febuxostat Intermediate Purity >99.0% Factory

Short Description:

Chemical Name: Ethyl 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate

CAS: 161797-99-5

Purity: >99.0% (HPLC)

Appearance: Light Yellow to Off-White Powder

Intermediate of Febuxostat (CAS: 144060-53-7)

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Ruifu Chemical Supply Febuxostat Related Intermediates:
Febuxostat CAS 144060-53-7
Ethyl 2-Chloroacetoacetate CAS 609-15-4
4-Hydroxythiobenzamide CAS 25984-63-8
Ethyl 2-(3-Cyano-4-Hydroxyphenyl)-4-Methyl-1,3-Thiazole-5-Carboxylate CAS 161798-02-3
Ethyl 2-(3-Cyano-4-Isobutoxyphenyl)-4-Methyl-5-Thiazolecarboxylate CAS 160844-75-7
Ethyl 2-(3-Formyl-4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161798-01-2
Ethyl 2-(3-Formyl-4-Isobutoxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161798-03-4
Ethyl 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161797-99-5

Chemical Properties:

Chemical Name	Ethyl 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate
Synonyms	Febuxostat Intermediate
CAS Number	161797-99-5
CAT Number	RF-PI1122
Stock Status	In Stock, Production Capacity 100 Tons/Year
Molecular Formula	C13H13NO3S
Molecular Weight	263.31
Melting Point	180℃
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	Light Yellow to Off-White Powder
Identification	By HPLC; By HNMR
Loss on Drying	<0.50%
Residue on Ighition	<0.30%
Single Impurity	<0.50%
Total Impurities	<1.00%
Purity / Analysis Method	>99.0% (by HPLC)
Test Standard	Enterprise Standard
Usage	Intermediate of Febuxostat (CAS: 144060-53-7)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

FAQ:

Application:

Ethyl 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate (CAS: 161797-99-5) is used in the synthesis of Febuxostat (CAS: 144060-53-7), a xanthine oxidase/xanthine dehydrogenase inhibitor. Used for treatment of hyperuricemia and chronic gout. 40-120 mg/day febuxostat was proven effective in lowering serum urate levels when administered to manage hyperuricemia in patients with gout. Fabuxostat was discovered by Teijin Pharmaceuticals and licensed to TAP Pharmaceuticals (which is currently part of Takeda Pharmaceuticals) and was approved in the U.S. for the treatment of hyperuricemia in patients with gout.